ArticleCNS oncology2014

Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomas.

Vincent A van Vugt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.